Skip to content
Menu

Organon & Co. OGN

Full chart Compare
Set alert

Price alert · OGN

All alert types
13.90 USD -0.01 (-0.04%)

As ofNov 20, 2026, 2:48 PM EST

13.90 Day range 13.91
5.70 52-week range 13.92
YTD
+93.93%
1 year
+95.02%

5D +0.01 (+0.07%)

13.8813.8913.9013.91ThuFriMonTueWed13.90
Market cap
3.65B
Revenue (ttm)
6.10B
Profit margin
3.49%
EPS (ttm)
0.78
Shares out
262.62M
P/E ratio
17.83
Forward P/E
3.81
Dividend
0.08 (0.58%)
Ex-dividend date
Nov 9, 2026
YTD return
+93.93%
1-year return
+95.02%
Volume
887.68K
Avg volume
2.71M
Open
13.91
Previous close
13.91
Day's range
13.90 – 13.91
52-week range
5.70 – 13.92
Beta
1.49
Price target
10.33 (-25.7%)
Earnings date
Feb 11, 2027
50-day average
13.77
200-day average
11.84

Key statistics

Enterprise value
10.75B
Price / sales
0.60
Price / book
3.06
Payout ratio
10.26%
Revenue growth
-1.70%
Free cash flow
721.37M
Total cash
1.46B
Total debt
8.55B
Return on equity
20.29%
Short % of float
8.52%

Fundamental scorecard

12 of 25 checks passed on OGN’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 3 of 5
  • Growth 1 of 5
  • Profitability 4 of 5
  • Financial health 1 of 5
  • Dividend 3 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
OGN Revenue — quarterly 1.57B
OGN Net income — quarterly 164.00M
OGN EPS — quarterly 0.62

Earnings

OGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20260.92———
Oct 30, 2026Sep 30, 20260.880.94+0.06+6.82%
Jul 31, 2026Jun 30, 20260.850.850.000.00%
Apr 30, 2026Mar 31, 20260.830.71-0.12-14.46%
Feb 12, 2026Dec 31, 20250.730.63-0.10-13.70%
Nov 10, 2025Sep 30, 20250.931.01+0.08+8.60%

Upgrades / downgrades

OGN analyst upgrades and downgrades
DateFirmActionFromTo
Apr 29, 2026BNP ParibasdownOutperformNeutral
Apr 28, 2026Piper SandlerupUnderweightNeutral
Feb 24, 2026BarclaysmainUnderweightUnderweight
Dec 9, 2025Barclaysinit—Underweight
Nov 11, 2025JP MorganmainUnderweightUnderweight
Nov 11, 2025Morgan StanleymainEqual-WeightEqual-Weight

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
organon.com

News

Your note

Sign in to keep a note on OGN — it syncs with the Stock Master app.

Insider holders

OGN insider holders
InsiderRelationLatest transactionDateShares held
ALI KEVINChief Executive OfficerPurchaseMay 4, 2025282,731
ARJONA FERREIRA JUAN CAMILOOfficerConversion of Exercise of derivative securityNov 5, 202641,565
COX CARRIE SMITHOfficer and DirectorPurchaseNov 11, 20250
FALCIONE AARONOfficerConversion of Exercise of derivative securityMar 30, 2026101,431
KARP DANIELOfficerConversion of Exercise of derivative securityMar 30, 202669,547
MORRISSEY JOSEPH T JRChief Executive OfficerConversion of Exercise of derivative securityNov 12, 2026153,316

Institution ownership

OGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.16%31,921,897444.19MSep 29, 2026
Pentwater Capital Management Lp7.68%20,180,000280.80MSep 29, 2026
Vanguard Portfolio Management LLC5.85%15,353,306213.64MSep 29, 2026
Vanguard Capital Management LLC4.54%11,916,620165.82MSep 29, 2026
FIL LTD4.00%10,504,377146.17MSep 29, 2026
State Street Corporation3.72%9,759,303135.80MSep 29, 2026

Fund ownership

OGN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%15,638,261217.61MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,332,789115.95MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%6,024,69983.83MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.45%3,815,00153.09MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.15%3,010,25541.89MJun 29, 2026
NexPoint Funds I-NexPoint Merger Arbitrage Fund1.03%2,705,08037.64MJun 29, 2026